Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Author:

Surie Diya,Bonnell Levi,Adams Katherine,Gaglani Manjusha,Ginde Adit A.,Douin David J.,Talbot H. Keipp,Casey Jonathan D.,Mohr Nicholas M.,Zepeski Anne,McNeal Tresa,Ghamande Shekhar,Gibbs Kevin W.,Files D. Clark,Hager David N.,Shehu Arber,Frosch Anne P.,Erickson Heidi L.,Gong Michelle N.,Mohamed Amira,Johnson Nicholas J.,Srinivasan Vasisht,Steingrub Jay S.,Peltan Ithan D.,Brown Samuel M.,Martin Emily T.,Khan Akram,Bender William S.,Duggal Abhijit,Wilson Jennifer G.,Qadir Nida,Chang Steven Y.,Mallow Christopher,Rivas Carolina,Kwon Jennie H.,Exline Matthew C.,Lauring Adam S.,Shapiro Nathan I.,Halasa Natasha,Chappell James D.,Grijalva Carlos G.,Rice Todd W.,Stubblefield William B.,Baughman Adrienne,Womack Kelsey N.,Hart Kimberly W.,Swan Sydney A.,Zhu Yuwei,DeCuir Jennifer,Tenforde Mark W.,Patel Manish M.,McMorrow Meredith L.,Self Wesley H.,Calhoun Nicole,Herrick Judy,Hoffman Eric,McKillop Amanda,Murthy Kempapura,Smith Michael,Zayed Martha,De Souza Lesley,Kozikowski Lori-Ann,Ouellette Scott,Ashok Kiran,Gole Susan,King Alexander,Mehkri Omar,Poynter Bryan,ten Lohuis Caitlin,Stanley Nicholas,Caspers Sean,Hendrickson Audrey,Kaus Olivia,Taghizadeh Leyla,Tordsen Walker,Aston Valerie,Bowers Robert,Jorgensen Jeffrey,King Jennifer,Ali Harith,Rothman Richard E.,Chen Jen-Ting,Nair Rahul,Allada Gopal,Briceno Genesis,Giovanni Shewit,Hubel Kinsley A.,Martinez Jesus,Oh Minn,Pak Jonathan,Pena Jose,Gordon Alexandra Jun,Levitt Joe,Perez Cynthia,Roque Jonasel,Visweswaran Anita,Karow Sarah,Khan Maryiam,Klingler Austin,Pannu Sarah,Smith David,Schwartz Elizabeth,Snyder Connor,So Madison,So Preston,Swoope Gabrielle,Weigand Michael,Carricato Michael,Chambers Ian,Driver Conner,Goff Jennifer,Huynh David,Jensen Kelly,Chandrasekaran Sukantha,Frankel Trevor,Garner Omai,Fairfield Catherine,Landers Shannon,Nassar Paul,Williams Cameron,Gershengorn Hayley,Bielak Ramsay,Blair Christopher,Fitzsimmons William J.,Fong Rebecca,Gilbert Julie,McSpadden EJ,Thomas Lara,Truscon Rachel,Valvano Weronika Damek,Anderson Layla A.,Crider Christine D.,Paulson Thomas C.,Steinbock Kyle A.,Blair Marica,Ezzell Lauren J.,Hargrave Samarian J.,Kampe Christy,Johnson Jakea,Luther Jennifer L.,McHenry Rendie E.,Peterson Bryan P. M.,Pulido Claudia Guevara,Short Laura L.,Whitsett Margaret E.,Hicks Madeline,Landreth Leigha,LaRose Mary,Parks Lisa,Babcock Hilary,Hink Tiffany,Jolani Kevin,McDonald David,O’Neal Caroline,Parikh Bijal,Parrish Katie,Samuels Carleigh, ,

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference10 articles.

1. CDC. COVID data tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Accessed September 4, 2022. https://covid.cdc.gov/covid-data-tracker/#variant-proportions

2. Effectiveness and durability of the BNT162b2 vaccine against Omicron sublineages in South Africa.;Collie;N Engl J Med,2022

3. Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Bernal JL. Effectiveness of the COVID-19 vaccines against severe disease with Omicron sub-lineages BA.4 and BA.5 in England. medRxiv [Preprint posted online September 1, 2022]. https://www.medrxiv.org/content/10.1101/2022.08.31.22279444v1.full.pdf

4. Kislaya I, Casaca P, Borges V, SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using electronic health records in Portugal. medRxiv [Preprint posted online July 25, 2022]. https://www.medrxiv.org/content/10.1101/2022.07.25.22277996v1.full.pdf

5. Tseng HF, Ackerson BK, Bruxvoort KJ, Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. medRxiv [Preprint posted online October 1, 2022]. https://www.medrxiv.org/content/medrxiv/early/2022/10/01/2022.09.30.22280573.full.pdf?%253fcollection=

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3